Derma Sciences (DSCI) to Acquire BioD in ~$77.8M Deal

Go back to Derma Sciences (DSCI) to Acquire BioD in ~$77.8M Deal

Derma Sciences to Acquire BioD, Solidify Its Leadership Position in Advanced Wound Care and Regenerative Products

July 28, 2016 7:30 AM EDT

Immediately accretive transaction will bring four proprietary high-margin product families and revenue of $22 million for the trailing 12 months ended June 30, 2016 Will add 235 independent sales representatives and seven direct sales representatives with no call-point or customer overlap BioD shareholders to make concurrent $2 million equity investment

Conference call to be held today at 9:00 a.m. Eastern time

PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (Nasdaq: DSCI), a tissue... More

Derma Sciences to Sell First Aid Products Division for Approximately $12.2 Million

July 27, 2016 7:30 AM EDT

Company also realized $7.6 million of proceeds from the sale of Comvita Limited common stock during the second quarter

PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the signing of a definitive agreement to sell its First Aid Division (FAD) to Dukal Corporation for approximately $12.2 million, including inventory. Dukal is a privately-held supplier of a broad range of best-in-class disposable medical products and patient-care items for all medical markets, with headquarters in... More